Next-IO™ PSCA x CD3 Therapeutic Bispecific Antibody Program

About This Program

This program aims to develop PSCA x CD3 therapeutic bispecific antibody for bladder carcinoma immunotherapy.

Rationale for our program:

PSCA x CD3

PSCA is a cell surface protein that binds to the surface of the membrane via a glycosylphosphatidylinositol (GPI)-anchor. PSCA is upregulated in several refractory cancers, including prostate, bladder and pancreatic cancer.

Highlight functions:

Next-IO™ PSCA x CD3 Therapeutic Bispecific Antibody ProgramFig.1 Putative PSCA signaling pathway and PSCA-targeted immunotherapy. (Norihisa, 2010)

Supporting Data

The following data support the rationale for the development of PSCA x CD3 BiAbs with an improved therapeutic index for the treatment of prostate cancer.

Next-IO™ PSCA x CD3 Therapeutic Bispecific Antibody Program (Feldmann, 2012)

Prostate Cancer

Next-IO™ PSCA x CD3 Therapeutic Bispecific Antibody Program

Ongoing Clinical Trials

Program Plan

Creative Biolabs has extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

Next-IO™ PSCA x CD3 Therapeutic Bispecific Antibody Program

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop PSCA x CD3 therapeutic bispecific antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.

Here are two ways for your choice, and please contact us for more details.

1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.

2) Become a licensed candidate for our programs.

With our quality control protocol and knowledge of global regulatory requirements, we can help our partners further their programs with more chances to succeed. Look forward to cooperating with you in the near future.

References

  1. Norihisa S.; et al. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clinical Cancer Research. 2010, 16(14):3533-3538.
  2. Feldmann A.; et al. Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells. The Journal of Immunology. 2012, 189(6):3249-3259.

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.